Skip to content
Beryl Drugs logo

Beryl Drugs

524606 BSE
₹24.98 down 0.87 (3.37%)
Market Cap
₹12.71 Cr
P/E
20.64

Beryl Drugs (BERLDRG) share price was ₹25.85 at the 28 Oct 2026 close; market capitalisation ₹13.15 Cr; P/E (TTM) 21.36; sector Healthcare. The share price rose 12.4% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 56.7% year on year to ₹7.57 Cr and net profit was ₹0.22 Cr, against ₹0.02 Cr a year earlier (compared with Jun 2025). Promoters held 27.97% of Beryl Drugs in Sep 2026, up 0.15 percentage points from Jun 2026. Its Tapetide Score is 56/100 (Good) as of 28 Oct 2026.

Close 28 Oct 2026 ₹25.85 +1.91 +7.98% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹12.71 Cr
P/E (TTM)
20.64
EBITDA
₹2.40 Cr
Return on Equity
4.3%
Debt to Equity
0.25
Book Value
₹19.45
EPS (TTM)
₹1.21
52W High
₹27.90
52W Low
₹15.92

Price-based figures as of 29 Oct 2026, 10:33 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,763.6034.994,23,147 Cr5.060.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,678.5087.842,56,934 Cr15.330.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,588.3072.031,74,524 Cr9.500.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,195.10108.451,18,604 Cr22.380.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,183.2026.331,18,025 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,338.8034.671,11,747 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.2032.711,10,289 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Beryl Drugs (this company)
₹24.9820.6413 Cr1.280.00%4.30%8.89%22 Cr1 Cr
Median 8 companies₹1,564.4034.831,18,314 Cr4.710.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

56 Good
Overall score

Data confidence 100/100

Category scores

Quality Good 59
Returns, margins, earnings quality 22% weight
Valuation Good 57
Cheap vs sector & own history 24% weight
Growth Weak 44
Sales & profit trajectory 9% weight
Financial Health Weak 42
Solvency, leverage, coverage 9% weight
Momentum Strong 82
Trend strength, vol-adjusted 12% weight
Ownership Average 51
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company has reduced debt.
  • Debtor days have improved from 79.4 to 40.6 days.
  • Company's working capital requirements have reduced from 55.4 days to 40.4 days

Weaknesses

4
  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of 6.04% over past five years.
  • Promoter holding is low: 27.8%
  • Company has a low return on equity of 6.39% over last 3 years.

Technical Indicators

Oscillators

Bearish

Bearish
2
Neutral
7
Bullish
0

Overall

Bullish

Bearish
2
Neutral
7
Bullish
10

Moving Averages

Bullish

Bearish
0
Neutral
0
Bullish
10

Growth Rate

Revenue Growth
-14.6% lower than 3Y

change over 1 year

Net Income Growth
-33.33% lower than 3Y

change over 1 year

Cash Flow Change
10.94%

change over 1 year

EBITDA Margin Change
7.26%

change over 1 year Operating margin 8.59% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
8.18
8.09
7.66
3.21
6.29
5.64
5.4
5.22
4.83
5.16
3.85
5.47
7.57
Expenses
7.05
7.37
6.87
3.19
5.3
5.08
4.81
4.72
4.28
4.43
4.05
4.13
6.92
Operating Profit
1.13
0.72
0.79
0.02
0.99
0.56
0.59
0.5
0.55
0.73
-0.2
1.34
0.65
OPM %
13.81%
8.9%
10.31%
0.62%
15.74%
9.93%
10.93%
9.58%
11.39%
14.15%
-5.19%
24.5%
8.59%
Other Income
0
0
0
0
0
0
0
0
0
0
0
0
0
Interest
0.12
0.1
0.11
0.13
0.21
0.12
0.12
0.08
0.1
0.08
0.09
0.07
0.06
Depreciation
0.28
0.29
0.31
0.32
0.28
0.33
0.31
0.32
0.38
0.39
0.32
0.4
0.32
PBT
0.73
0.33
0.37
-0.43
0.5
0.11
0.16
0.1
0.07
0.26
-0.61
0.87
0.27
Tax %
27.4%
18.18%
16.22%
-16.28%
26%
90.91%
62.5%
-50%
71.43%
96.15%
-72.13%
34.48%
18.52%
Net Profit
0.53
0.27
0.31
-0.35
0.37
0.01
0.05
0.15
0.02
0.01
-0.17
0.56
0.22
EPS (₹)
1.05
0.53
0.61
-0.69
0.73
0.02
0.1
0.3
0.04
0.02
-0.34
1.1
0.43
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
13.23
12.99
10.9
15.08
12.81
12.78
14.03
14.48
26.84
26.73
21.15
18.81
22.05
Expenses
12.5
12.49
10.96
14.04
11.78
11.87
12.58
14.04
24.84
24.45
19.91
16.87
19.53
Operating Profit
0.73
0.5
-0.06
1.04
1.03
0.91
1.45
0.44
2
2.28
1.24
1.94
2.52
OPM %
5.52%
3.85%
-0.55%
6.9%
8.04%
7.12%
10.33%
3.04%
7.45%
8.53%
5.86%
10.31%
11.43%
Other Income
0.18
0.37
0.27
0.69
0.24
0.23
0.64
0.16
0.27
0.4
1.41
0.49
0
Interest
0.26
0.21
0.2
0.13
0.15
0.32
0.47
0.46
0.47
0.47
0.54
0.35
0.3
Depreciation
0.52
0.41
0.38
0.33
0.32
0.66
1.27
1.09
0.81
1.2
1.26
1.49
1.43
PBT
0.13
0.25
-0.37
1.27
0.8
0.16
0.35
-0.95
0.99
1.01
0.85
0.59
0.79
Tax %
38.46%
32%
18.92%
22.05%
26.25%
68.75%
31.43%
-30.53%
22.22%
23.76%
34.12%
27.12%
—
Net Profit
0.08
0.17
-0.45
0.99
0.59
0.05
0.24
-0.66
0.77
0.77
0.57
0.42
0.62
EPS (₹)
0.16
0.34
-0.89
1.95
1.16
0.1
0.47
-1.3
1.52
1.52
1.12
0.83
1.21
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
5.09
5.09
5.09
5.09
5.09
5.09
5.09
5.09
5.09
5.09
5.09
5.09
Reserves
1.4
1.57
0.79
1.57
2.43
2.53
2.84
2.2
2.97
3.83
4.39
4.79
Borrowings
1.72
1.69
1.72
1.48
3.25
5.23
5.12
5.29
4.54
5.09
4.12
2.44
Other Liabilities
2.71
1.8
2.85
2.69
3.8
4.07
5.6
5.25
4.92
3.48
2.38
2.65
Total Liabilities
10.92
10.15
10.45
10.83
14.57
16.92
18.65
17.83
17.52
17.49
15.98
14.97
Fixed Assets
2.43
2.44
2.25
2.22
1.96
8.6
7.52
6.04
6.03
6.17
6.24
7.04
CWIP
0.24
0
0
0.08
6.24
0
0
0
0
0
0
0
Investments
0.68
0.68
0.49
0.22
0.48
0.56
0.12
0.16
0.15
0
0
0
Other Assets
7.57
7.03
7.71
8.31
5.89
7.76
11.01
11.63
11.34
11.32
9.74
7.93
Total Assets
10.92
10.15
10.45
10.83
14.57
16.92
18.65
17.83
17.52
17.49
15.98
14.97
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0.7
-0.13
0.37
-0.1
3.35
0.18
0.34
-0.29
2.48
0.82
3.29
3.65
Investing
0.02
0.17
0.32
-0.03
-5.01
-1.55
0.26
0.54
-1.3
-1.08
-1.05
-2.16
Financing
-0.09
-0.23
-0.19
-0.36
1.62
1.67
-0.54
-0.43
-1.17
0.1
-1.56
-2.03
Net Cash Flow
0.63
-0.19
0.5
-0.49
-0.04
0.3
0.06
-0.18
0.01
-0.16
0.69
-0.54
Free Cash Flow
0.47
-0.33
0.19
-0.01
-2.87
-1.7
0.1
0.1
1.73
-0.51
1.1
-0.17
CFO/OP
125
6
-833
1
350
36
25
-43
127
45
280
196
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
102
101
102
117
98.02
98.53
118
112
93.83
104
94.23
40.56
Inventory Days
64.34
65.28
151
53.1
39.74
487
1,135
—
246
—
—
—
Days Payable
69.91
34.34
65.24
57.03
93.6
755
1,110
—
758
—
—
—
Cash Conversion Cycle
96.5
132
189
113
44.16
-170
143
112
-419
104
94.23
40.56
Working Capital Days
38.35
58.44
67.31
71.89
-6.55
13.99
38.76
47.14
46.51
57.9
68
40.36
ROCE %
5.2%
5.56%
-2.26%
11.94%
9.94%
4.06%
2.86%
-3.82%
11.6%
11.05%
10.07%
7.25%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Beryl Drugs insights

59 extracted metrics + investor summaries across FY10–FY27.

Shareholding Pattern

Public63.47%Others8.56%Promot.27.97%As ofSep 2026

Documents

Frequently Asked Questions about Beryl Drugs

What does Beryl Drugs Ltd do?
Incorporated in 1993, Beryl Drugs Ltd is in the business of pharmaceuticals manufacturing[1]
Where is Beryl Drugs Ltd (BERLDRG) listed?
Beryl Drugs Ltd trades under code 524606 on the BSE.
Which sector does Beryl Drugs Ltd belong to?
Beryl Drugs Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Beryl Drugs Ltd?
Beryl Drugs Ltd has a market capitalisation of ₹12.71 Cr as of 29 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Beryl Drugs Ltd?
Beryl Drugs Ltd trades at a PE ratio of 20.64 as of 29 Oct 2026, on earnings per share of ₹1.21, against a book value of ₹19.45 per share.
What is the 52-week high and low of Beryl Drugs Ltd?
Over the last 52 weeks Beryl Drugs Ltd has traded between ₹15.92 and ₹27.9 as of 29 Oct 2026.
What is the Return on Equity (ROE) of Beryl Drugs Ltd?
Beryl Drugs Ltd reported a return on equity of 4.30%. Its debt-to-equity ratio is 0.25.

Company Information

Incorporated in 1993, Beryl Drugs Ltd is in the business of pharmaceuticals manufacturing[1]

Website beryldrugs.com
Listed 2006-07-25
Face Value ₹ 10
Shares Outstanding 50,88,141

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524606.md for Beryl Drugs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month